ANPCY News and Press, Angle Plc Surrey ADR From 02/08/21

Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy Findings support ANGLE's plan...

MAJOR EUROPEAN CONSORTIUM PUBLISHES RESULTS OF LARGE-SCALE INVESTIGATION DEMONSTRATING KEY ADVANTAGES OF PARSORTIX SYSTEM IN LUNG CANCER Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype GUILDFORD, SURREY / ACCESSWIRE / January 29,...

PARSORTIX SYSTEM IS "IDEAL CTC PLATFORM FOR USE IN CLINICAL TRIALS AND CLINICAL PATIENT MANAGEMENT" Independent research confirms high performance of Parsortix ® system in isolating CTCs for downstream analysis GUILDFORD, SURREY / ACCESSWIRE / January 20, 2021 / ANGLE plc...

GUILDFORD, SURREY / ACCESSWIRE / January 12, 2021 / ANGLE plc (AIM:AGL) and OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following a formal tender process, it has appointed PricewaterhouseCoopers LLP ("PwC") as its auditor for the Company and its subsidiaries for the f...

Angle Plc (ANPCY): 1H GAAP EPS of -£2.76.Revenue of £0.24M (-36.8% Y/Y)Press Release For further details see: Angle Plc reports 1H results

Full Class II De Novo FDA Submission seeking clearance of the Parsortix system for metastatic breast cancer has successfully completed FDA administrative review ANGLE believes that the earliest prospect of FDA clearance is Q2 CY21* GUILDFORD, SURREY / ACCESSWIRE / October 20,...

GUILDFORD, SURREY / ACCESSWIRE / September 28, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 30 October 2018 ("the Remuneration Policy"), the Remunera...

Full Class II De Novo FDA Submission seeking clearance of the Parsortix system for metastatic breast cancer Potential to be the first ever FDA clearance for a system to harvest intact cancer cells from a simple blood draw for subsequent analysis GUILDFORD, SURREY / ACCESSWIRE / Sept...

Published research using the Parsortix system to isolate CTC clusters from blood confirms the role of intra-tumour hypoxia in promoting metastatic breast cancer Study highlights the potential for Parsortix liquid biopsy in cancer drug discovery GUILDFORD, SURREY / ACCESSWIRE / Septe...

GUILDFORD, SURREY / ACCESSWIRE / September 2, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 30 June 2020 on Thursday 29 October 2020. This date is in line with COVID-19 guidance provided by AIM R...